lenvatinib
Showing 1 - 25 of 239
Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib plus sintilimab, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Lenvatinib plus sintilimab
- Lenvatinib
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Nov 2, 2022
Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma Non-resectable
- Lenvatinib Plus I-125 Seed Brachytherapy
- Lenvatinib
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Nov 2, 2022
Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)
Recruiting
- Unresectable Hepatocellular Carcinoma
- D-TACE
- +3 more
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Oct 14, 2022
GBM Trial (Lenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields))
Not yet recruiting
- GBM
- Lenvatinib
- +2 more
- (no location specified)
Aug 2, 2023
Endometrial Cancer, Endometrial Adenocarcinoma Trial in Guangzhou (Cadonilimab, Lenvatinib)
Not yet recruiting
- Endometrial Cancer
- Endometrial Adenocarcinoma
- Cadonilimab
- Lenvatinib
-
Guangzhou, ChinaSun Yat-sen University Cancer Cetntre
Apr 9, 2023
Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)
Recruiting
- Ovarian Clear Cell Carcinoma
- Gynecologic Cancer
- Lenvatinib
- Pembrolizumab
-
Boston, MassachusettsDana Farber Cancer Institute
Oct 13, 2022
Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)
Not yet recruiting
- Hepatocellular Carcinoma
- Cryoablation
- +2 more
- (no location specified)
May 31, 2023
Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)
Recruiting
- Solid Tumor, Adult
- Tislelizumab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Sep 13, 2023
Efficacy of Lenvatinib in Differentiated Thyroid Cancer
Recruiting
- Differentiated Thyroid Cancer
- Gender
- Lenvatinib
-
Rome, ItalyRegina Elena National Cancer Institute
Mar 16, 2023
Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)
Recruiting
- Advanced Hepatocellular Carcinoma
- Lenvatinib
- +2 more
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Oct 20, 2022
Hepatocellular Carcinoma Trial (TACE(transcatheter arterial chemoembolization), lenvatinib, Icaritin soft capsules)
Not yet recruiting
- Hepatocellular Carcinoma
- TACE(transcatheter arterial chemoembolization)
- +2 more
- (no location specified)
Jun 5, 2023
Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)
Not yet recruiting
- Gastric Cancer Metastatic to Liver
- Cryoablation
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 6, 2023
Solid Tumors Trial in Chongqing (F520, Lenvatinib)
Recruiting
- Solid Tumors
- F520
- Lenvatinib
-
Chongqing, Chongqing, ChinaChongqing University Cancer Hospital
Feb 13, 2023
Melanoma Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)
Recruiting
- Melanoma
- Tislelizumab
- +2 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 8, 2022
Advanced Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cryoablation, Sintilimab, Lenvatinib)
Recruiting
- Advanced Intrahepatic Cholangiocarcinoma
- Cryoablation
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 28, 2023
PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,
Not yet recruiting
- PD-1 Refractory Advanced Melanoma
- Responder-Derived Fecal microbiota transplantation (R-FMT
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 1, 2023
Mucosal Melanoma Trial in Wollstonecraft (Pembrolizumab, Lenvatinib)
Not yet recruiting
- Mucosal Melanoma
- Pembrolizumab
- Lenvatinib
-
Wollstonecraft, New South Wales, AustraliaMelanoma Institute Australia
Sep 15, 2022
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer Trial in Tampa (Pembrolizumab, Lenvatinib)
Active, not recruiting
- Neuroendocrine Tumors
- +2 more
- Pembrolizumab
- Lenvatinib
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 24, 2023
Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)
Recruiting
- Advanced Biliary Tract Cancer
- Sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 22, 2023
Fumarate Hydratase Deficient Renal Cell Carcinoma Trial (Tislelizumab, Lenvatinib)
Not yet recruiting
- Fumarate Hydratase Deficient Renal Cell Carcinoma
- Tislelizumab
- Lenvatinib
- (no location specified)
May 18, 2023
Hepatocellular Carcinoma Trial in Shanghai (lenvatinib, TACE)
Active, not recruiting
- Hepatocellular Carcinoma
- lenvatinib
- TACE
-
Shanghai, ChinaHuashan hospital
Jul 29, 2022
Prostate Cancer Metastatic, Neuroendocrine Tumors Trial in Atlanta, Ann Arbor (Pembrolizumab, Lenvatinib)
Recruiting
- Prostate Cancer Metastatic
- Neuroendocrine Tumors
- Pembrolizumab
- Lenvatinib
-
Duarte, California
- +2 more
Jan 18, 2023
Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)
Not yet recruiting
- Advanced Hepatocellular Carcinoma
- Lenvatinib
- +2 more
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Feb 7, 2023